Axsome Therapeutics, Inc. (AXSM)
NASDAQ: AXSM · Real-Time Price · USD
104.33
+0.51 (0.49%)
Apr 23, 2025, 4:00 PM EDT - Market closed
Axsome Therapeutics Revenue
In the year 2024, Axsome Therapeutics had annual revenue of $385.69M with 42.53% growth. Axsome Therapeutics had revenue of $118.77M in the quarter ending December 31, 2024, with 66.04% growth.
Revenue (ttm)
$385.69M
Revenue Growth
+42.53%
P/S Ratio
12.95
Revenue / Employee
$564,704
Employees
683
Market Cap
5.08B
Revenue Chart
Revenue History
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 89.33B |
Merck & Co. | 64.17B |
AbbVie | 56.33B |
AstraZeneca | 54.07B |
Novartis AG | 51.72B |
Eli Lilly and Company | 45.04B |
Thermo Fisher Scientific | 42.88B |
AXSM News
- 1 day ago - Axsome Therapeutics to Participate in Upcoming Investor Conferences - GlobeNewsWire
- 15 days ago - Axsome Therapeutics to Report First Quarter 2025 Financial Results on May 5 - GlobeNewsWire
- 19 days ago - Axsome Therapeutics Presents Positive Pivotal Phase 3 Results of the ACCORD-2 Trial of AXS-05 in Alzheimer's Disease Agitation and the SYMPHONY Trial of AXS-12 in Narcolepsy at the 2025 American Academy of Neurology (AAN) Annual Meeting - GlobeNewsWire
- 22 days ago - Axsome's depression treatment fails to meet main goal of late-stage study - Reuters
- 4 weeks ago - Axsome Therapeutics' ADHD drug meets main goal in late-stage study - Reuters
- 4 weeks ago - Axsome: The Alzheimer's Agitation Program For AXS-05 - Seeking Alpha
- 2 months ago - Axsome Says Symbravo Hits Primary Goal In Late-Stage Migraine Trial In Patients Experiencing Inadequate Response To Commonly Used Drugs - Benzinga
- 2 months ago - Axsome Q4 Earnings: Revenues Rising, Skepticism Lingering - Seeking Alpha